Get the Stockscreener App
4.08
1.45%
-0.06
After Hours:
4.06
-0.02
-0.49%
Hcw Biologics Inc stock is traded at $4.08, with a volume of 26,309.
It is down -1.45% in the last 24 hours and down -26.49% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
See More
Previous Close:
$4.14
Open:
$4.06
24h Volume:
26,309
Relative Volume:
0.01
Market Cap:
$8.78M
Revenue:
$3.50M
Net Income/Loss:
$-37.33M
P/E Ratio:
-4.08
EPS:
-1
Net Cash Flow:
$-19.15M
1W Performance:
-10.13%
1M Performance:
-26.49%
6M Performance:
-66.07%
1Y Performance:
-80.81%
1-Day Range:
$4.01
$4.17
1-Week Range:
$3.815
$4.54
52-Week Range:
$2.77
$100.80
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
4.08 | 8.91M | 3.50M | -37.33M | -19.15M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Hcw Biologics Inc Stock (HCWB) Latest News
Historical volatility pattern of HCW Biologics Inc. visualized2025 Key Lessons & Safe Investment Capital Preservation Plans - newser.com
HCW Biologics Inc. stock volume spike explainedRecession Risk & Safe Entry Point Identification - newser.com
Fed Watch: What is the earnings history of HCW Biologics Inc2025 Buyback Activity & Verified Chart Pattern Signals - خودرو بانک
Can momentum traders help lift HCW Biologics Inc.July 2025 Fed Impact & Consistent Profit Alerts - newser.com
Can HCW Biologics Inc. hit a new high this month2025 Institutional Moves & Daily Chart Pattern Signals - newser.com
Should you hold or exit HCW Biologics Inc. nowQuarterly Earnings Summary & Detailed Earnings Play Strategies - newser.com
Published on: 2025-09-20 08:29:13 - خودرو بانک
What’s next for HCW Biologics Inc. stock priceStop Loss & Long-Term Growth Stock Strategies - newser.com
What MACD signals say about HCW Biologics Inc.Earnings Trend Report & Low Risk Entry Point Tips - newser.com
Is HCW Biologics Inc. forming a reversal pattern2025 Trading Volume Trends & Daily Chart Pattern Signal Reports - newser.com
Smart Money: Will HCW Biologics Inc. outperform the market in YEARJuly 2025 Summary & Consistent Return Strategy Ideas - خودرو بانک
Does HCW Biologics Inc. show high probability of reboundMarket Sentiment Report & Real-Time Market Sentiment Alerts - newser.com
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing - GlobeNewswire
What to expect from HCW Biologics Inc. in the next 30 daysWeekly Profit Summary & Safe Capital Investment Plans - newser.com
Macro Review: Can RLI Corp. reach resistance levels soonWeekly Risk Summary & Real-Time Stock Price Movement Reports - khodrobank.com
HCW Biologics Inc. stock trendline breakdownWeekly Risk Report & Growth-Oriented Investment Plans - newser.com
Aug Sentiment: Can HCW Biologics Inc. lead its sector in growth2025 Stock Rankings & Daily Profit Focused Stock Screening - خودرو بانک
Earnings visualization tools for HCW Biologics Inc.July 2025 Retail & Weekly High Return Opportunities - newser.com
Trade Report: Can HCW Biologics Inc stock double in the next yearCEO Change & Intraday High Probability Setup Alerts - خودرو بانک
Will HCW Biologics Inc. bounce back from current supportRate Hike & Fast Exit Strategy with Risk Control - newser.com
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program - ADVFN Ltd
How institutional ownership impacts HCW Biologics Inc. stock2025 Short Interest & Community Verified Trade Signals - newser.com
Growth Review: Is HCW Biologics Inc. stock good for income investorsDip Buying & Momentum Based Trading Signals - khodrobank.com
HCW Biologics Delays Q2 10-Q Filing - MSN
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics - Investing News Network
$115 Million Biotech Deal: Wugen's Off-the-Shelf CAR-T Cell Therapy Gets Major Fidelity Backing - Stock Titan
Can HCW Biologics Inc. be recession proofTrade Risk Summary & Free High Accuracy Swing Entry Alerts - خودرو بانک
New Highs: Will HCW Biologics Inc outperform tech stocks2025 Technical Patterns & Daily Volume Surge Trade Alerts - خودرو بانک
Institutional scanner results for HCW Biologics Inc.Analyst Downgrade & Weekly High Return Stock Forecasts - newser.com
HCW Biologics Designates One of Its Proprietary - GlobeNewswire
Sentiment Review: Can SLNH be the next market leaderInsider Buying & Capital Efficient Trading Techniques - خودرو بانک
Movement Recap: Is HCW Biologics Inc forming a breakout pattern2025 Macro Impact & Low Volatility Stock Recommendations - خودرو بانک
HCW Biologics Advances Lead Product Candidate HCW11-040 to Late Stage IND-Enabling Studies for Solid Tumor Treatment - Quiver Quantitative
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development - GlobeNewswire
Breakthrough Cancer Drug Outperforms Keytruda: HCW Biologics' HCW11-040 Shows Promise Without Cytokine Storm - Stock Titan
HCW Biologics (NASDAQ:HCWB) Trading Down 12.3% – What’s Next? - Defense World
Will HCW Biologics Inc. see short term momentumWeekly Stock Recap & Free Community Consensus Stock Picks - newser.com
Earnings Report: How sensitive is HCW Biologics Inc to inflationLayoff News & Low Drawdown Trading Strategies - خودرو بانک
Trading Recap: How sensitive is HCW Biologics Inc to inflationChart Signals & Weekly Momentum Picks - خودرو بانک
Breakout Watch: Can Bellevue Life Sciences Acquisition Corp Equity Warrant maintain sales growthMarket Activity Report & Safe Capital Growth Tips - خودرو بانک
Bank Watch: Will HCW Biologics Inc. outperform the market in YEARDividend Hike & Daily Oversold Stock Bounce Ideas - khodrobank.com
Why Is HCW Biologics Stock Surging 102% Overnight? - inkl
HCW Biologics Reports Positive Results from Non-Human - GlobeNewswire
Does HCW Biologics Inc. have high return on assetsShare Buyback & Capital Efficient Trade Techniques - Lancaster City Council
Will HCW Biologics Inc. outperform tech stocksWeekly Trade Summary & Risk Controlled Daily Trade Plans - Lancaster City Council
HCW Biologics announces results from second-gen T-cell engager programs - TipRanks
HCW Biologics Reports Positive Preclinical Results for Second-Generation T-Cell Engagers in Solid Tumors - Quiver Quantitative
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):